Brain drug SAGE-718 tested in healthy people – no cure yet

NCT ID NCT03844906

Completed Knowledge-focused Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage study tested a drug called SAGE-718 in 40 healthy adults. Researchers used a ketamine challenge to see how the drug affects brain electrical activity and safety. The goal was to gather basic information, not to treat any illness. This is a first step toward understanding if SAGE-718 might be useful for brain conditions in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-718
What this could lead to: If successful, this could help researchers understand how SAGE-718 affects brain activity, potentially guiding future studies for conditions like Alzheimer's or Parkinson's.
What could go wrong: This is a very early Phase 1 study in only 40 healthy people, not patients. It is designed to test safety and brain effects, not to treat any disease. Results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Sage Investigational Site

Long Beach, California, 90806, United States
Sage Investigational Site

Berlin, New Jersey, 08009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.